^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Multiple Myeloma
    Drug:lenalidomide (TNFα inhibitor, IL-6 inhibitor, IL-12 inhibitor) +
    Ninlaro (ixazomib) (Proteasome inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    FDA
    Published date:
    11/20/2015
    Excerpt:
    NINLARO is a proteasome inhibitor indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.
    Secondary therapy:
    dexamethasone
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    Oncology Central
    Title:

    NICE approves ixazomib in combination with lenalidomide–dexamethasone to treat relapsed or refractory multiple myeloma

    Published date:
    01/23/2023
    Excerpt:
    The National Institute for Health and Care Excellence (NICE) published a guidance document recommending the use of ixazomib (brand name Ninlaro) in combination with lenalidomide and dexamethasone in patients with refractory or relapsed multiple myeloma.
    Secondary therapy:
    dexamethasone
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Multiple Myeloma:…the NCCN Panel has included ixazomib/lenalidomide/dexamethasone as an option (category 2B) for treatment of patients with newly diagnosed MM....the NCCN Panel has included ixazomib/lenalidomide/dexamethasone as a category 1, preferred regimen option for previously treated MM.
    Secondary therapy:
    dexamethasone